AQST · Aquestive Therapeutics, Inc.

Summary

Aquestive Therapeutics entered into Amendment No. 1 to its Purchase and Sale Agreement with RTW funds, extending the Marketing Approval Deadline to June 30, 2027, and concurrently issued a warrant for 375,000 shares at $4.00 per share expiring March 3, 2029, while RTW-affiliated funds committed to purchase at least $5 million of common stock within 90 days. The company also reported Q4 and full year 2025 financial results with total revenues of $13.0 million and $44.5 million, respectively.

Key takeaways

• Amendment No. 1 extends Marketing Approval Deadline from original date to June 30, 2027
• Issued warrant to RTW funds for up to 375,000 shares of common stock at $4.00/share, expiring March 3, 2029
• RTW-affiliated funds commit to purchase ≥$5,000,000 common stock within 90 days per Rule 415(a)(4)
• Q4 2025 revenues $13.0 million (up 10% from $11.9 million Q4 2024)
• Full year 2025 revenues $44.5 million
• Q4 2025 net loss $31.9 million ($0.26/share) including one-time legal expenses